Back to search results

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Hormone Receptor-positive Breast Cancer · Hormone Receptor Positive HER-2 Negative Breast Cancer · Metastatic Breast Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Yale School of Medicine, New Haven, Connecticut, United States

  • Moffitt Cancer Center, Tampa, Florida, United States

  • Massachusetts General Hospital, Boston, Massachusetts, United States

  • Henry Ford Hospital, Detroit, Michigan, United States

  • Sarah Cannon Research Institute, Nashville, Tennessee, United States

  • Texas Oncology Baylor University Medical Center, Dallas, Texas, United States

  • Virginia Cancer Specialists, Fairfax, Virginia, United States

  • Hospital 12 de Octubre, Usera, Madrid, Spain

  • Hospital Universitari Vall d'Hebron (VHIO), Barcelona, Spain

  • Hospital Universitario Ramón y Cajal, Madrid, Spain

  • NEXT Oncology Hospital Quironsalud, Madrid, Spain

  • Sarah Cannon Research Institute UK, London, London, United Kingdom

  • The Christie NHS Foundation Trust, Manchester, Wilmslow Rd, United Kingdom

  • The Clatterbridge Cancer Centre, Liverpool, United Kingdom

View source on ClinicalTrials.gov(opens in a new tab)